Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY0206 vs Salvage Chemotherapy in FLT3-ITD+ R/R AML
NCT05876832Phase 3Not yet recruiting
- Sponsor
- Yiling Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of XY0206 in acute myeloid leukemia (AML), sponsored by Yiling Pharmaceutical. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05876832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876832.